Biomimetic hybrid gel compositions and methods of use
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61L-027/54
A61K-035/39
A61K-035/28
A61K-035/30
A61K-035/55
A61L-027/26
A61L-027/38
A61L-027/52
A61K-009/00
A61K-047/36
A61K-045/06
출원번호
US-0023843
(2014-09-30)
등록번호
US-9981067
(2018-05-29)
국제출원번호
PCT/US2014/058397
(2014-09-30)
국제공개번호
WO2015/048774
(2015-04-02)
발명자
/ 주소
Brekke, John H.
O'Brien, Timothy
출원인 / 주소
BIOACTIVE REGENERATIVE THERAPEUTICS, INC.
대리인 / 주소
Pepper Hamilton LLP
인용정보
피인용 횟수 :
0인용 특허 :
11
초록▼
Disclosed herein are dry blends of polyanionic and polycationic macromolecules, solvating fluids serving as cell suspension fluids, hybrid gel compositions, and methods for treatment of patients with endocrine disorders by transplantation with such compositions. Hybrid gel compositions that promote
Disclosed herein are dry blends of polyanionic and polycationic macromolecules, solvating fluids serving as cell suspension fluids, hybrid gel compositions, and methods for treatment of patients with endocrine disorders by transplantation with such compositions. Hybrid gel compositions that promote a microenvironment suitable for cell viability and growth while maintaining a sufficient structural integrity for three-dimensional cell culture are also disclosed.
대표청구항▼
1. A hybrid gel composition comprising: dextran sulfate;at least one polycationic macromolecule;a solvating fluid;embedded endocrine cells; andembedded pluripotent cells;wherein the dextran sulfate, at least one polycationic macromolecule, and solvating fluid form a three-dimensional hybrid gel comp
1. A hybrid gel composition comprising: dextran sulfate;at least one polycationic macromolecule;a solvating fluid;embedded endocrine cells; andembedded pluripotent cells;wherein the dextran sulfate, at least one polycationic macromolecule, and solvating fluid form a three-dimensional hybrid gel composition comprising a network of insoluble, polyelectrolytic complexes, wherein the network of insoluble, polyelectrolytic complexes has regions of unreacted dextran sulfate and regions of unreacted polycationic macromolecules. 2. The composition of claim 1, further comprising hyaluronan. 3. The composition of claim 2, further comprising peptide fragments covalently bonded to hyaluronan. 4. The composition of claim 1, wherein the dextran sulfate is of a low molecular weight of about 5 kilodaltons to about 40 kilodaltons. 5. The composition of claim 1, wherein the composition has a Young's modulus of about 0.5 to about 60 kiloPascals. 6. The composition of claim 1, wherein the at least one polycationic macromolecule is chitosan. 7. The composition of claim 6, wherein the chitosan is deacetylated to at least 90%. 8. The composition of claim 1, wherein the embedded endocrine cells and embedded pluripotent cells are suspended in the solvating fluid. 9. The composition of claim 1, wherein the embedded endocrine cells are selected from the group consisting of pancreatic islet cells, adrenal cells, thyroid cells, parathyroid cells, parafollicular cells, pinealocytes, pituitary cells, neurosecretory cells, and any combination thereof. 10. The composition of claim 1, wherein the dextran sulfate is sulfated from about 10% to about 13%. 11. The composition of claim 1, wherein the dextran sulfate is sulfated from about 17% to about 22%. 12. The composition of claim 1, wherein the dextran sulfate is of a high molecular weight at about 40 kilodaltons to about 1,000 kilodaltons. 13. The composition of claim 1, wherein the dextran sulfate and each of the polycationic macromolecules are at a charge ratio of n+/n− equal to about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 2.0, about 3.0, about 4.0, about 5.0, about 6.0, about 7.0, or about 8.0. 14. The composition of claim 1, wherein the solvating fluid has an osmolarity of about 255 mOsmol/L to about 300 mOsmol/L. 15. The composition of claim 1, further comprising one or more biologically active agents. 16. The composition of claim 15, wherein the biologically active agent is selected from the group consisting of growth factors, morphogens, hormones, cytotoxic agents, other therapeutic pharmaceutical compounds, and combinations thereof. 17. The composition of claim 15, wherein the biologically active agent is selected from the group consisting of exendin-4, betacellulin, peptides that specifically bind an α5β1 integrin, islet neogenesis-associated protein, islet neogenesis-associated protein fractions, islet neogenesis-associated protein derivatives, serum albumin, and combinations thereof. 18. The composition of claim 15, wherein the biologically active agent is selected from the group consisting of extracellular matrix glycoproteins, proteoglycans, glycosaminoglycans, and combinations thereof. 19. The composition of claim 1, further comprising peptide fragments covalently bonded to dextran sulfate. 20. The composition of claim 1, further comprising peptide fragments covalently bonded to at least one polycationic macromolecule. 21. A hybrid gel composition comprising: at least one polyanionic macromolecule;at least one lyophilized polycationic macromolecule;a solvating fluid; andcells selected from the group consisting of pluripotent stem cells, their differentiated progeny, and combinations thereof;wherein the at least one polycationic macromolecule and solvating fluid form a three-dimensional hybrid gel composition comprising a network of insoluble, polyelectrolytic complexes, wherein the network of insoluble, polyelectrolytic complexes has regions of unreacted polycationic macromolecules. 22. The composition of claim 21, wherein the solvating fluid comprises at least one dissolved polyanionic macromolecule, ½ normal saline, and glycerol phosphate. 23. The composition of claim 21, further comprising hyaluronan. 24. The composition of claim 23, further comprising peptide fragments covalently bonded to the hyaluronan. 25. The composition of claim 21, wherein the polyanionic macromolecule is of a low molecular weight of about 5 kilodaltons to about 40 kilodaltons. 26. The composition of claim 21, wherein the composition has a Young's modulus of about 0.5 to about 60 kiloPascals. 27. The composition of claim 21, wherein the at least one polycationic macromolecule is chitosan. 28. The composition of claim 27, wherein the chitosan is deacetylated to at least 90%. 29. The composition of claim 21, wherein the cells are suspended in the solvating fluid. 30. The composition of claim 21, wherein the at least one polyanionic macromolecule is dextran sulfate. 31. The composition of claim 21, wherein the at least one polyanionic macromolecule is sulfated from about 10% to about 13%. 32. The composition of claim 21, wherein the at least one polyanionic macromolecule is sulfated from about 17% to about 22%. 33. The composition of claim 31, wherein the at least one polyanionic macromolecule is of a high molecular weight at about 40 kilodaltons to about 1,000 kilodaltons. 34. The composition of claim 21, wherein the polyanionic macromolecule and the polycationic macromolecules are each at a charge ratio of n+/n− equal to about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 2.0, about 3.0, about 4.0, about 5.0, about 6.0, about 7.0, or about 8.0. 35. The composition of claim 21, wherein the solvating fluid has an osmolarity of about 255 mOsmol/L to about 300 mOsmol/L. 36. The composition of claim 21, further comprising one or more biologically active agents. 37. The composition of claim 36, wherein the biologically active agent is selected from the group consisting of growth factors, morphogens, hormones, cytotoxic agents, other therapeutic pharmaceutical compounds, and combinations thereof. 38. The composition of claim 36, wherein the biologically active agent is selected from the group consisting of exendin-4, betacellulin, peptides that specifically bind an α5β1 integrin, islet neogenesis-associated protein, islet neogenesis-associated protein fractions, islet neogenesis-associated protein derivatives, serum albumin, and combinations thereof. 39. The composition of claim 36, wherein the biologically active agent is selected from the group consisting of extracellular matrix glycoproteins, proteoglycans, glycosaminoglycans, and combinations thereof. 40. The composition of claim 21, further comprising peptide fragments covalently bonded to at least one polyanionic macromolecule. 41. The composition of claim 21, further comprising peptide fragments covalently bonded to at least one polycationic macromolecule. 42. The composition of claim 21, wherein the pluripotent stem cells are selected from the group consisting of endocrine progenitor cells, induced pluripotent stem cells, mesenchymal stem cells, and any combination thereof. 43. The composition of claim 1, wherein the embedded pluripotent cells are selected from the group consisting of endocrine progenitor cells, induced pluripotent stem cells, mesenchymal stem cells, and any combination thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (11)
Bellamkonda Ravi ; Ranieri John P.,CHX ; Aebischer Patrick,CHX, Bioartificial extracellular matrix containing hydrogel matrix derivatized with cell adhesive peptide fragment.
Abatangelo, Giovanni; Callegaro, Lanfranco, Biological material containing bone marrow stem cells partially or completely differentiated into connective tissue cells and a hyaluronic acid ester matrix.
Giovanni Abatangelo IT; Lanfranco Callegaro IT; Randell G. Young ; Josephine Mary Murphy ; David Jordan Fink ; Scott Philip Bruder ; Francis Peter Barry ; Sudhakar Kadiyala ; Arnold I. Caplan, Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative.
Collombel Christian (Lyon FRX) Damour Odile (Saint Genis Laval FRX) Gagnieu Christian (Lyon FRX) Poinsignon Frederique (Lyon FRX) Echinard Christian (Gemenos FRX) Marichy Jacques (Lyon FRX), Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.